NeuroMetrix, Inc. (NURO): Company Short-Term Debts

Public company logo of NeuroMetrix Corporation (NURO)

NeuroMetrix, Inc. (NURO) is protected by strict FDA controls and unique patents for pain management equipment. The business focuses on creating wearable gadgets, offering patients a medication alternative through nerve stimulation. This daily price chart illustrates the asset's dynamics, with a value of 0.00. However, liquidity shortages and insurance reimbursement complexities create significant financial risks.

NURO (NeuroMetrix) Company Short-Term Debts history from 07/04/2022 to 05/11/2025

Analytical breakdowns for NeuroMetrix Corporation (NURO)

- stock price and consensus target price:
Stock Price NeuroMetrix|NURO - Analyst Median Target
- stock exchange capitalization data:
Market Capitalization NeuroMetrix, Inc.|NURO - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share NeuroMetrix|NURO - Book Capitalization|Market Value to Book Value Ratio neurometrix.com|NURO - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio NeuroMetrix, Inc.|NURO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital NeuroMetrix, Inc.|NURO - Company Total Debt Obligations|Debt to Book Capitalization Ratio NeuroMetrix, Inc.|NURO - Company Long-Term Indebtedness|Company Short-Term Debt NeuroMetrix|Quick Liquidity Indicator neurometrix.com
- net income and valuation multiples indicators:
NURO - Profit After Payment of Taxes
Fundamental company analysis:NURO - NeuroMetrix
Flagship merchandise of NeuroMetrix Corporation

This indicator aggregates all obligations with a maturity of up to one year, allowing for an assessment of immediate liquidity and capital refinancing risk. By analyzing the short-term debt burden, investors determine the financial stability of NeuroMetrix, Inc. (NURO) as it scales partnerships for the implementation of Quell neurostimulators, where control over current liabilities is critical for the development of non-pharmacological pain treatment technologies.

Direct competitors

Intuitive - Company Short-Term Debts|Short-Term Debt Volume Danaher Corporation DHR|BDX: Company Short-Term Debts|Company Current Liabilities STERIS Group|WST (West Pharmaceutical Services) - Company Short-Term Debts|Company Short-Term Debts baxter.com|Company Short-Term Debt Masimo (MASI)|Company Short-Term Debt STVN (Stevanato Group SpA)|Teleflex Inc - Company Current Liabilities|Company Short-Term Loans and Borrowings MMSI|Envista Holdings - Company Short-Term Debts|Short-Term Debt Volume icumed.com ICUI|Dentsply Sirona (XRAY) - Company Short-Term Debt|Company Short-Term Indebtedness LMAT|Company Short-Term Debt AtriCure Corp|STAAR Surgical Co (STAA) - Short-Term Debt Volume|Company Current Liabilities NAGE (ChromaDex)|Amount of Current Liabilities ZIMV|Company Short-Term Debt AngioDynamics ANGO|Company Short-Term Loans and Borrowings CERS|TKNO: Company Current Liabilities|MGRM - Company Short-Term Debts|sharpstechnology.com (STSS) - Company Short-Term Debt|Company Current Liabilities InfuSystem Holdings, Inc.|UTMD (Utah Medical Products, Inc.) - Company Short-Term Debts|Short-Term Debt KORU Medical Systems Inc. KRMD|Company Short-Term Debt Nyxoah, S.A. (NYXH)|Microbot Medical, Inc - Company Short-Term Indebtedness|Pro-Dex, Inc. - Company Current Liabilities|Amount of Current Liabilities ZTEK (zentek.com)|ELUT - Company Short-Term Debt|Short-Term Debt Volume Milestone Scientific Inc MLSS|NEXGEL, Inc (NXGL) - Company Short-Term Debt|Company Short-Term Indebtedness RVP|HBIO (Harvard Bioscience) - Company Short-Term Debts|Short-Term Debt femasys.com FEMY|Company Current Liabilities MHUA (MeihuaMed)|Company Short-Term Debts predictive-oncology.com (POAI)|Company Short-Term Debt Callan JMB CJMB|Company Short-Term Loans and Borrowings ATRI